Lenacapavir offers twice-yearly HIV prevention with near-complete protection in clinical trials. Clinical trials show ...

The Global Fund to Fight AIDS, Tuberculosis and Malaria (the Global Fund) has announced that it has signed an access agreement with Pharmaceutical Company Gilead Sciences to procure lenacapavir, a ...

The Minister’s address was particularly notable for the announcement of a planned rollout of lenacapavir, a biannual ...

Just a week had remained before scientists in South Africa were to begin clinical trials of an HIV vaccine, and hopes were ...

JOHANNESBURG (AP) — Just a week had remained before scientists in South Africa were to begin clinical trials of an HIV ...

The news devastated the researchers, who live and work in a region where more people live with HIV than anywhere else in the ...

The fact that lenacapavir will soon be available to patients is a testament to the strength of America's biopharmaceutical ...

A twice-yearly injection could help Australia eliminate HIV, but experts are sounding the alarm over its prohibitive cost.

A pivotal moment in the fight to end AIDS -- ensuring lifesaving innovation reaches those who need it most, wherever they live ...

There are over 100,000 HIV+ Texans. Trump's 'big beautiful' bill would slash funding for federal HIV prevention, medications, ...

Gilead Sciences and the Global Fund to Fight AIDS, Tuberculosis and Malaria said on Wednesday they had finalized plans to supply a long-acting HIV prevention drug to low-income countries, despite the ...

Gilead will supply lenacapavir to Global Fund countries for HIV prevention, but questions remain amid PEPFAR cuts and funding ...